New Mental Health Manual

Amid controversy, the American Psychiatric Association has approved the fifth edition of its guidebook on mental disorders.

Written byBeth Marie Mole
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Early color illustrations of psychiatric treatment methods, as drawn by physician Serefeddin Sabuncuoglu (1385-1470).Wikimedia, Serafeddin SabuncuogluThe American Psychiatric Association’s (APA) board of trustees last week (December 1) approved the text for the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)—an instructional book for doctors to diagnose mental health illnesses. Although the board consulted more than 1,500 mental health experts while updating the content for the latest edition, which it started in 1999, the draft revision released in 2010 has met with considerable controversy.

Despite the “inevitable disagreements about some of the proposals, . . . [the manual] reflects our best scientific understanding of psychiatric disorders and will optimally serve clinical and public health needs,” APA President Dilip Jeste said in a statement. “Our hope,” he added, “is that the DSM-5 will lead to more accurate diagnoses, better access to mental health services, and improved patient outcomes."

Among the controversies raised by the new guidelines was the APA’s decision to merge several autism-spectrum disorders into one classification, which critics claim could cause milder disorders in the spectrum to be overlooked. The fifth edition also includes the newly defined “disruptive mood dysregulation disorder,” which is aimed at stemming the diagnosis of bipolar disorders in children with sudden, violent tendencies. But ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies